Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVEYKS)

Drug Name
JSP191 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hematopoietic stem cell transplantation QB63 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMVEYKS

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tyrosine-protein kinase Kit (KIT) DTT KIT 3.766 7.517 7.379 6.916
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hematopoietic stem cell transplantation
ICD Disease Classification QB63
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase Kit (KIT) DTT KIT 2.06E-01 -0.1 -0.14
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05357482) Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia. U.S.National Institutes of Health.
2 Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1316-1327.